John C. Brady

718 total citations
18 papers, 488 citations indexed

About

John C. Brady is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John C. Brady has authored 18 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in John C. Brady's work include Colorectal Cancer Treatments and Studies (6 papers), Angiogenesis and VEGF in Cancer (4 papers) and Lung Cancer Treatments and Mutations (4 papers). John C. Brady is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Angiogenesis and VEGF in Cancer (4 papers) and Lung Cancer Treatments and Mutations (4 papers). John C. Brady collaborates with scholars based in United States, Hong Kong and United Kingdom. John C. Brady's co-authors include John F. Carlquist, Ann Allen, Marlene J. Egger, Sanjeev Trehan, Benjamin D. Horne, Joseph B. Muhlestein, Jeffrey L. Anderson, Andrew B. Nixon, Herbert I. Hurwitz and Mark D. Starr and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Radiology.

In The Last Decade

John C. Brady

18 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John C. Brady United States	12	133	123	119	112	106	18	488
Emanuela Mancini Italy	23	111 0.8×	310 2.5×	227 1.9×	102 0.9×	48 0.5×	51	1.2k
Mona Aarenstrup Karlsen Denmark	12	127 1.0×	93 0.8×	121 1.0×	43 0.4×	48 0.5×	26	669
Kristian Bartnes Norway	17	158 1.2×	25 0.2×	205 1.7×	46 0.4×	197 1.9×	41	727
A. Roszak Poland	15	180 1.4×	166 1.3×	224 1.9×	15 0.1×	142 1.3×	82	721
Marianna Ferrara Italy	14	94 0.7×	169 1.4×	238 2.0×	23 0.2×	49 0.5×	29	547
Colette Chapuis‐Cellier France	15	150 1.1×	111 0.9×	157 1.3×	12 0.1×	53 0.5×	40	604
Chen‐Chung Chu Taiwan	18	134 1.0×	140 1.1×	78 0.7×	11 0.1×	288 2.7×	30	685
Tyler O. Kirby United States	15	173 1.3×	140 1.1×	185 1.6×	10 0.1×	52 0.5×	27	608
L J Farrow United Kingdom	8	98 0.7×	140 1.1×	120 1.0×	21 0.2×	41 0.4×	16	463

Countries citing papers authored by John C. Brady

Since Specialization

Citations

This map shows the geographic impact of John C. Brady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Brady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Brady more than expected).

Fields of papers citing papers by John C. Brady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Brady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Brady. The network helps show where John C. Brady may publish in the future.

Co-authorship network of co-authors of John C. Brady

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Brady. A scholar is included among the top collaborators of John C. Brady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Brady. John C. Brady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Nixon, Andrew B., Yingmiao Liu, Qian Yang, et al.. (2024). Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. Prostate Cancer and Prostatic Diseases. 28(2). 355–362. 2 indexed citations

Nixon, Andrew B., Fábio C. P. Navarro, Katherine I. Zhou, et al.. (2024). Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.. Journal of Clinical Oncology. 42(16_suppl). 4025–4025. 1 indexed citations

Nixon, Andrew B., Lee McDaniel, Jingquan Jia, et al.. (2023). Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.. Journal of Clinical Oncology. 41(16_suppl). 4040–4040. 1 indexed citations

Jia, Jingquan, Lauren E. Howard, Yingmiao Liu, et al.. (2022). Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. Cancer Chemotherapy and Pharmacology. 89(3). 413–422. 6 indexed citations

Liu, Yingmiao, Jing Lyu, Kirsten B. Burdett, et al.. (2020). Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics. 19(10). 2146–2154. 15 indexed citations

Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, et al.. (2019). Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecologic Oncology. 153(3). 555–561. 27 indexed citations

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2018). Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Molecular Cancer Therapeutics. 17(10). 2248–2256. 15 indexed citations

Liu, Yingmiao, Zhenhua Yuan, Dadong Zhang, et al.. (2017). Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. Journal of Clinical Oncology. 35(15_suppl). 11546–11546. 1 indexed citations

Ronald, James, Andrew B. Nixon, Daniele Marin, et al.. (2017). Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Radiology. 285(1). 311–318. 14 indexed citations

10.

Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, et al.. (2016). Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Medicine. 5(9). 2249–2260. 17 indexed citations

11.

Nixon, Andrew B., Alexander B. Sibley, Ace J. Hatch, et al.. (2016). Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. Journal of Clinical Oncology. 34(15_suppl). 3597–3597. 12 indexed citations

12.

Secord, Angeles Alvarez, David Tritchler, Yingmiao Liu, et al.. (2016). Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.. Journal of Clinical Oncology. 34(15_suppl). 5521–5521. 7 indexed citations

13.

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2015). Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics. 14(4). 1048–1056. 18 indexed citations

14.

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2014). Modulation of circulating protein biomarkers following TRC105 (anti‐endoglin antibody) treatment in patients with advanced cancer. Cancer Medicine. 3(3). 580–591. 23 indexed citations

15.

Strickler, John H., Shannon J. McCall, Andrew B. Nixon, et al.. (2013). Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investigational New Drugs. 32(2). 330–339. 18 indexed citations

16.

Nixon, Andrew B., Susan Halabi, Ivo Shterev, et al.. (2013). Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology. 31(15_suppl). 4520–4520. 17 indexed citations

17.

Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, et al.. (2013). A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas. The Oncologist. 18(3). 271–272. 36 indexed citations

18.

Anderson, Jeffrey L., Joseph B. Muhlestein, John F. Carlquist, et al.. (1999). Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection. Circulation. 99(12). 1540–1547. 258 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact